Abstract
The traditional use of Hypericum perforatum L. (St. Johns wort, Clusiaceae) in Western medicine was well known even before the 1600s: St. Johns extracts were used to relieve various types of nervous disease long before depression was recognized as a well described pathology. Today, random controlled trials clearly confirm the efficacy of this plant extract over placebo in the treatment of mild to moderately severe depression. Of the different classes of H. perforatum secondary metabolites, the prenylated acylphloroglucinol hyperforin has emerged as key player for anti-depressant activity. But as well as Hypericums anti-depressant property, several other pharmacological actions have now been documented – examples include anti-bacterial, anti-proliferative and anti-inflammatory - many of which may be related to hyperforin. These findings add support to the effectiveness of St. Johns wort as a folk remedy in common use for treating skin injuries, burns and neuralgias. This review gives a historical overview of the plant, including its medical uses, plus a look at the chemical structure of the most relevant phyto-constituents. This is followed by a close analysis of recent data regarding the biological effects of hyperforin, focusing on antiinflammatory and anti-tumor activities. The compounds clear and proven actions qualify it as an interesting lead candidate for countering inflammatory disease and cancer.
Keywords: Hypericin, angiogenesis, Anthraquinonic derivatives, anti-depressant, HIV-1 genome
Current Bioactive Compounds
Title: The Renaissance of Hypericum perforatum: Bio-Medical Research Catches Up with Folk Medicine
Volume: 3 Issue: 2
Author(s): Isabella Dell'Aica, Spiridione Garbisa and Rosy Caniato
Affiliation:
Keywords: Hypericin, angiogenesis, Anthraquinonic derivatives, anti-depressant, HIV-1 genome
Abstract: The traditional use of Hypericum perforatum L. (St. Johns wort, Clusiaceae) in Western medicine was well known even before the 1600s: St. Johns extracts were used to relieve various types of nervous disease long before depression was recognized as a well described pathology. Today, random controlled trials clearly confirm the efficacy of this plant extract over placebo in the treatment of mild to moderately severe depression. Of the different classes of H. perforatum secondary metabolites, the prenylated acylphloroglucinol hyperforin has emerged as key player for anti-depressant activity. But as well as Hypericums anti-depressant property, several other pharmacological actions have now been documented – examples include anti-bacterial, anti-proliferative and anti-inflammatory - many of which may be related to hyperforin. These findings add support to the effectiveness of St. Johns wort as a folk remedy in common use for treating skin injuries, burns and neuralgias. This review gives a historical overview of the plant, including its medical uses, plus a look at the chemical structure of the most relevant phyto-constituents. This is followed by a close analysis of recent data regarding the biological effects of hyperforin, focusing on antiinflammatory and anti-tumor activities. The compounds clear and proven actions qualify it as an interesting lead candidate for countering inflammatory disease and cancer.
Export Options
About this article
Cite this article as:
Dell'Aica Isabella, Garbisa Spiridione and Caniato Rosy, The Renaissance of Hypericum perforatum: Bio-Medical Research Catches Up with Folk Medicine, Current Bioactive Compounds 2007; 3 (2) . https://dx.doi.org/10.2174/157340707780809644
DOI https://dx.doi.org/10.2174/157340707780809644 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Interleukin-1β Receptor Antagonism Prevents Cognitive Impairment Following Experimental Bacterial Meningitis
Current Neurovascular Research Access to Opioids for Patients with Advanced Disease
Current Pharmaceutical Design Metabotropic Glutamate Receptor Genes as Candidates for Pharmacogenetic Studies of Current and Future Antipsychotic Agents in Schizophrenia
Current Pharmacogenomics Cathepsin D as a Promising Target for the Discovery of Novel Anticancer Agents
Current Cancer Drug Targets Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
Current Pharmaceutical Design School-based Prevention for Adolescent Internet Addiction: Prevention is the Key. A Systematic Literature Review
Current Neuropharmacology A Clinical View of BDNF-TrkB Signaling in the Treatment of Major Depression
Current Signal Transduction Therapy Structural Characterization of Amyloid β17-42 Dimer by Potential of Mean Force Analysis: Insights from Molecular Dynamics Simulations
Protein & Peptide Letters “Bridge Proteins” Link Inflammation and Metabolic Diseases: Potential Targets for Therapeutics
Current Protein & Peptide Science Bcl-2 Family Proteins Regulate Apoptosis and Epithelial to Mesenchymal Transition by Calcium Signals
Current Pharmaceutical Design Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease
Current Bioactive Compounds Obesity Pharmacotherapy: Current Perspectives and Future Directions
Current Cardiology Reviews International Conference on Personalized Medicine: “Genes and Medicine” 19-20 September 2009, Hong Kong Science Park, Hong Kong SAR
Current Pharmacogenomics and Personalized Medicine TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry Immunoglobulin Free Light Chains in Immune Responses
Current Immunology Reviews (Discontinued) Detection of Klebsiella Antibodies and HLA-B27 Allelotypes Could be Used in the Early Diagnosis of Ankylosing Spondylitis with a Potential for the Use of “Low Starch Diet” in the Treatment
Current Rheumatology Reviews Editorial (Towards Better Understanding on Psychiatric Disorder, Ocular Diseases, Heart Disease and Cancer)
Current Molecular Medicine Biochemical Screening for in utero Drug Exposure
Drug Metabolism Letters Proteomics Approach to Illustrate Drug Action Mechanisms
Current Drug Discovery Technologies